89. リンパ脈管筋腫症 Lymphangioleiomyomatosis Clinical trials / Disease details
臨床試験数 : 38 / 薬物数 : 38 - (DrugBank : 15) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 118
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02737202 (ClinicalTrials.gov) | April 2016 | 31/3/2016 | Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis | Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis | Pulmonary Lymphangioleiomyomatosis | Drug: saracatinib | Baylor College of Medicine | University of Cincinnati;Brigham and Women's Hospital;Stanford University;Loyola University;University of South Florida;National Institutes of Health (NIH) | Terminated | 18 Years | 65 Years | Female | 28 | Phase 2 | United States |
| 2 | NCT02116712 (ClinicalTrials.gov) | August 2014 | 15/4/2014 | The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1) | The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1) | Pulmonary Lymphangioleiomyomatosis | Drug: Saracatinib | Tony Eissa | University of Texas;University of Cincinnati | Completed | 18 Years | 65 Years | Both | 9 | Phase 1 | United States |